Allergan, Inc. Earnings Call Nuggets: 2Q Guidance, Duet Dividends
Larry Biegelsen – Wells Fargo Securities: I guess I will just ask about the guidance. The midpoint of the 2Q guidance I think is 5% for sales, 10% for EPS. Those numbers are below the full-year midpoint. Is that due to FX or are there other factors in the second quarter we should be aware of?
A Closer Look: Allergan Earnings Cheat Sheet>>
Jeffrey L. Edwards – EVP, Finance and Business Development, CFO: Well, no. I think as is typically the case Larry, we put forth a set of numbers that represent our conservative estimates. To the extent we can perform better than that, it’s certainly our expectation to perform better than that.
Gregory Waterman – Goldman Sachs: For the Duet Dividends program I was hoping you could help us think about the potential magnitude of the 2Q impact I guess embedded in this. To what extent can we focus on the first quarter of last year as a useful analogue?
David E.I. Pyott – Chairman, President and CEO: Yeah, well, when you across the history, the swings are really very, very large. If we look at the U.S. figures alone for last year, the effect of this promotion was an increase of over 40% in sales, Q1 versus Q1. So, clearly there’s a big rise and fall of what goes into channel, and this year, as I pointed out in my remarks, we compounded that with the switch of the size from 0.8 to 1 ml at the same price and we made it very clear we weren’t taking back the smaller size. So, the motivation to stock up was less than zero. And clearly, the sell-in of this promotion which started in the middle of April has been very strong. So, based on everything, we can see – you’ll see the flip around in Q2 with some very major filler growth across the world. So, we did this all for promotional reasons, as I stated. It was all due to be timed to just after what we had assumed would be the launch of Xeomin cosmetic at the AED.